BACKGROUND: Alzheimer's disease (AD) is the most common degenerative neurologic disorder. The onset of symptoms is insidious and follows a long period of progression of an asymptomatic pathology that proceeds in a precise anatomic and temporal sequence. Recent studies with quantitative magnetic resonance imaging techniques have shown the localization of the in vivo pathology of AD and its antecedent, mild cognitive impairment. The objective of the present study was to determine whether a sensitive and reliable marker for the presymptomatic phase of the disorder could be identified by longitudinal analysis of an initially asymptomatic, community-based population. METHODS: One hundred forty-eight healthy, cognitively normal participants in the Cardiovascular Health Study-Cognition Study had detailed clinical examinations and magnetic resonance imaging scans in 1998-1999 and 2002-2003. Modulated voxel-based morphometry was used to compare regional brain volumes in subjects who remained cognitively normal after 5 to 6 years of follow-up (n = 127) with those who developed probable AD during the same period (n = 21). RESULTS: Among normal subjects destined to develop AD, there was significant atrophy in the basal forebrain area as long as 4.5 years before the development of clinical symptoms. When the left hippocampus was also atrophic, the onset of dementia typically occurred earlier than in cases in which the atrophy was confined to basal forebrain. CONCLUSIONS: Atrophy in the basal forebrain precedes the development of AD in subjects with cognition judged to be normal by neuropsychological testing. The time required to develop dementia appears to be shortened if hippocampal atrophy is also present. These data indicate that atrophy restricted to medial basal forebrain is a biomarker that predicts development of probable AD in asymptomatic elderly subjects.
BACKGROUND:Alzheimer's disease (AD) is the most common degenerative neurologic disorder. The onset of symptoms is insidious and follows a long period of progression of an asymptomatic pathology that proceeds in a precise anatomic and temporal sequence. Recent studies with quantitative magnetic resonance imaging techniques have shown the localization of the in vivo pathology of AD and its antecedent, mild cognitive impairment. The objective of the present study was to determine whether a sensitive and reliable marker for the presymptomatic phase of the disorder could be identified by longitudinal analysis of an initially asymptomatic, community-based population. METHODS: One hundred forty-eight healthy, cognitively normal participants in the Cardiovascular Health Study-Cognition Study had detailed clinical examinations and magnetic resonance imaging scans in 1998-1999 and 2002-2003. Modulated voxel-based morphometry was used to compare regional brain volumes in subjects who remained cognitively normal after 5 to 6 years of follow-up (n = 127) with those who developed probable AD during the same period (n = 21). RESULTS: Among normal subjects destined to develop AD, there was significant atrophy in the basal forebrain area as long as 4.5 years before the development of clinical symptoms. When the left hippocampus was also atrophic, the onset of dementia typically occurred earlier than in cases in which the atrophy was confined to basal forebrain. CONCLUSIONS:Atrophy in the basal forebrain precedes the development of AD in subjects with cognition judged to be normal by neuropsychological testing. The time required to develop dementia appears to be shortened if hippocampal atrophy is also present. These data indicate that atrophy restricted to medial basal forebrain is a biomarker that predicts development of probable AD in asymptomatic elderly subjects.
Authors: R J Killiany; B T Hyman; T Gomez-Isla; M B Moss; R Kikinis; F Jolesz; R Tanzi; K Jones; M S Albert Journal: Neurology Date: 2002-04-23 Impact factor: 9.910
Authors: Howard J Aizenstein; V Andrew Stenger; Jennifer Cochran; Kristi Clark; Melissa Johnson; Robert D Nebes; Cameron S Carter Journal: Cereb Cortex Date: 2004-02 Impact factor: 5.357
Authors: Oscar L Lopez; William J Jagust; Steven T DeKosky; James T Becker; Annette Fitzpatrick; Corinne Dulberg; John Breitner; Constantine Lyketsos; Beverly Jones; Claudia Kawas; Michelle Carlson; Lewis H Kuller Journal: Arch Neurol Date: 2003-10
Authors: Lewis H Kuller; Oscar L Lopez; Anne Newman; Norman J Beauchamp; Greg Burke; Corinne Dulberg; Annette Fitzpatrick; Linda Fried; Mary N Haan Journal: Neuroepidemiology Date: 2003 Jan-Feb Impact factor: 3.282
Authors: Oscar L Lopez; Lewis H Kuller; Annette Fitzpatrick; Diane Ives; James T Becker; Norman Beauchamp Journal: Neuroepidemiology Date: 2003 Jan-Feb Impact factor: 3.282
Authors: Catriona D Good; Rachael I Scahill; Nick C Fox; John Ashburner; Karl J Friston; Dennis Chan; William R Crum; Martin N Rossor; Richard S J Frackowiak Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: Lubov E Zeifman; William F Eddy; Oscar L Lopez; Lewis H Kuller; Cyrus Raji; Paul M Thompson; James T Becker Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Stefan J Teipel; Thomas Meindl; Lea Grinberg; Michel Grothe; Jose L Cantero; Maximilian F Reiser; Hans-Jürgen Möller; Helmut Heinsen; Harald Hampel Journal: Hum Brain Mapp Date: 2010-07-29 Impact factor: 5.038
Authors: Michel Grothe; Laszlo Zaborszky; Mercedes Atienza; Eulogio Gil-Neciga; Rafael Rodriguez-Romero; Stefan J Teipel; Katrin Amunts; Aida Suarez-Gonzalez; Jose L Cantero Journal: Cereb Cortex Date: 2009-11-04 Impact factor: 5.357